Pantoprazole
نویسندگان
چکیده
منابع مشابه
Pantoprazole-related Symptomatic Hyponatremia
Hyponatremia is the most common electrolyte balance disorder, especially in the elderly and polymedicated population. The authors report the case of an 83-year-old man with symptomatic severe hyponatremia due to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) related to pantoprazole. Pantoprazole was discontinued and serum sodium levels reached normal values in two months. To t...
متن کاملBioequivalence Study of Pantoprazole Sodium-HPBCD and Conventional Pantoprazole Sodium Enteric-Coated Tablet Formulations
The objective of this study was to investigate the bioequivalence of two formulations of 40 mg pantoprazole sodium enteric-coated tablets: Tripepsa as the test and Pantocid as the reference. The two products were administered as a single oral dose according to a randomized two-phase crossover with a 1-month washout period in 25 healthy Indian volunteers. After drug administration, serial blood ...
متن کاملExfoliative erythrodermia induced by pantoprazole.
Although proton pump inhibitors are widely used, allergic reactions to this group of drugs are rarely reported. In this paper we present the case of a patient who developed a delayed reaction to pantoprazole. A 35-year-old female patient complained of generalised erythema with intense itching and desquamation for three weeks before consulting (Fig. 1). The rash was first noticed five days after...
متن کاملRabeprazole vs pantoprazole vs omeprazole
hour 23 (rabeprazole 100% vs. omeprazole 74%,. P < 0.02). Conclusions: Rabeprazole, 20 mg, demonstrated superior control of peptone mealstimulated . Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of. . new PPIs rabeprazole, pantoprazole and lansoprazole compared to omeprazole. Nov 1, 2007. Four studies of pantoprazole (Protonix) 40 mg versus omeprazole. Two studies of rab...
متن کاملPROTONIX®(pantoprazole sodium)Delayed-Release Tablets PROTONIX ®(pantoprazole sodium)For Delayed-Release Oral Suspension
DESCRIPTION The active ingredient in PROTONIX (pantoprazole sodium) Delayed-Release Tablets and PROTONIX (pantoprazole sodium) For Delayed-Release Oral Suspension is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]1H-benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion. Its empirical formula is C16H14F2N3NaO4S x 1.5...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Reactions Weekly
سال: 2021
ISSN: ['1179-2051', '0114-9954']
DOI: https://doi.org/10.1007/s40278-021-95958-0